 |
Section sizes
|
Section size for SARS-CoV-2 Omicron variant (45 sections)
| Section name |
Byte
count |
Section
total
|
| (Top) |
10,053 |
10,053
|
| Classification |
4,163 |
4,163
|
| History |
4,165 |
45,968
|
| Origin hypotheses |
7,639 |
7,639
|
| Spread |
34,164 |
34,164
|
| Reactions |
17 |
23,065
|
| Vaccine producers |
5,655 |
5,655
|
| World Health Organization |
4,477 |
4,477
|
| International response |
12,916 |
12,916
|
| Biology |
178 |
7,580
|
| Mutations |
7,402 |
7,402
|
| Subvariants |
6,637 |
50,957
|
| BA.2 |
2,155 |
28,523
|
| Spread |
15,098 |
15,098
|
| XE |
657 |
657
|
| BA.2.12 |
808 |
808
|
| BA.2.75 and BA.2.75.2 |
1,620 |
8,655
|
| XBB and XBB.1 |
4,777 |
4,777
|
| EG.5 and EG.5.1 |
2,258 |
2,258
|
| HV.1 |
1,096 |
1,096
|
| BA.2.86 |
54 |
54
|
| BA.4 and BA.5 |
11,747 |
15,649
|
| BQ.1 and BQ.1.1 |
3,902 |
3,902
|
| Later subvariants |
148 |
148
|
| Transmission |
286 |
10,268
|
| In humans |
8,184 |
8,184
|
| In non-human animals |
619 |
619
|
| Surfaces |
1,179 |
1,179
|
| Vaccine effectiveness |
10,251 |
15,400
|
| BA.1 and BA.2 |
1,635 |
1,635
|
| BA.4 and BA.5 |
2,761 |
3,514
|
| BQ.1 and BQ.1.1 |
753 |
753
|
| Vaccine adjustments |
4,295 |
4,295
|
| Signs and symptoms |
4,611 |
4,611
|
| Virulence |
3,887 |
3,887
|
| Diagnosis |
3,734 |
10,734
|
| PCR testing |
2,554 |
7,000
|
| BA.1 and BA.2 differences |
4,446 |
4,446
|
| Treatment |
5,865 |
5,865
|
| Epidemiology |
22,506 |
22,567
|
| Reported cases |
61 |
61
|
| See also |
773 |
773
|
| Notes |
26 |
26
|
| References |
30 |
30
|
| External links |
1,283 |
1,283
|
| Total |
221,525 |
221,525
|
| |